27553051|t|Intracameral cefuroxime in the prevention of postoperative endophthalmitis: an experience from Hong Kong
27553051|a|The purpose was to study the effect of introducing intracameral cefuroxime, which was compounded by a hospital pharmacy, on postoperative endophthalmitis in a tertiary eye centre in Hong Kong. All cases that underwent cataract surgeries over a 12-year period (January 2004 to December 2015) were included. The routine use of intracameral cefuroxime at the end of cataract surgery was introduced at our centre after April 2010. All cefuroxime aliquots were prepared by the hospital pharmacy using an aseptic compounding technique. The rates of postoperative endophthalmitis before April 2010 (Group 1, no intracameral cefuroxime) and after April 2010 (Group 2, routine use of intracameral cefuroxime) were compared. A total of 30,428 eyes (7,332 in Group 1 and 23,096 in Group 2) were studied. Eight cases developed postoperative endophthalmitis (1.09 in 1000; 0.11 %) in Group 1 whereas no cases developed endophthalmitis (0 %) in Group 2. The rate of reduction was statistically significant (p < 0.0001). Seven out of eight cases of endophthalmitis were confirmed by positive culture. Organisms identified were Group G Streptococcus (two cases), Group B Streptococcus, Staphylococcus aureus, Serratia marcescens, and coagulase-negative Staphylococcus (two cases). Antibiotic susceptibility testing results were available in six cases. Four out of six organisms were susceptible to the penicillin group. No adverse events related to the use of intracameral cefuroxime were encountered. The use of intracameral cefuroxime could significantly reduce the rate of postoperative endophthalmitis in a tertiary centre in Hong Kong. The use of aseptic compounding to prepare cefuroxime aliquots by hospital pharmacy appeared to be safe and efficacious.
27553051	0	12	Intracameral	T082	C1636767
27553051	13	23	cefuroxime	T109,T195	C0007562
27553051	31	41	prevention	T061	C0679698
27553051	45	74	postoperative endophthalmitis	T047	C1282227
27553051	79	89	experience	T041	C0596545
27553051	95	104	Hong Kong	T083	C0019907
27553051	124	129	study	T062	C2603343
27553051	134	140	effect	T080	C1280500
27553051	144	155	introducing	T169	C0579004
27553051	156	168	intracameral	T082	C1636767
27553051	169	179	cefuroxime	T109,T195	C0007562
27553051	191	201	compounded	T058	C0013164
27553051	207	224	hospital pharmacy	T093	C0260123
27553051	229	258	postoperative endophthalmitis	T047	C1282227
27553051	264	283	tertiary eye centre	T093	C0596660
27553051	287	296	Hong Kong	T083	C0019907
27553051	323	341	cataract surgeries	T061	C2939459
27553051	415	422	routine	T080	C0205547
27553051	423	426	use	T169	C0457083
27553051	430	442	intracameral	T082	C1636767
27553051	443	453	cefuroxime	T109,T195	C0007562
27553051	468	484	cataract surgery	T061	C2939459
27553051	536	546	cefuroxime	T109,T195	C0007562
27553051	547	555	aliquots	T081	C1510844
27553051	577	594	hospital pharmacy	T093	C0260123
27553051	604	611	aseptic	T080	C0232920
27553051	604	623	aseptic compounding	T058	C0013164
27553051	639	644	rates	T081	C1521828
27553051	648	677	postoperative endophthalmitis	T047	C1282227
27553051	697	702	Group	UnknownType	C0681860
27553051	706	708	no	T169	C0332197
27553051	709	721	intracameral	T082	C1636767
27553051	722	732	cefuroxime	T109,T195	C0007562
27553051	756	761	Group	UnknownType	C0681860
27553051	780	792	intracameral	T082	C1636767
27553051	793	803	cefuroxime	T109,T195	C0007562
27553051	838	842	eyes	T023	C0015392
27553051	853	858	Group	UnknownType	C0681860
27553051	875	880	Group	UnknownType	C0681860
27553051	920	949	postoperative endophthalmitis	T047	C1282227
27553051	976	981	Group	UnknownType	C0681860
27553051	1011	1026	endophthalmitis	T047	C0014236
27553051	1036	1041	Group	UnknownType	C0681860
27553051	1049	1053	rate	T081	C1521828
27553051	1057	1066	reduction	T080	C0392756
27553051	1071	1096	statistically significant	T081	C0237881
27553051	1139	1154	endophthalmitis	T047	C0014236
27553051	1173	1189	positive culture	T033	C0159125
27553051	1191	1200	Organisms	T001	C0029235
27553051	1217	1238	Group G Streptococcus	T007	C0318162
27553051	1252	1273	Group B Streptococcus	T007	C0038402
27553051	1275	1296	Staphylococcus aureus	T007	C0038172
27553051	1298	1317	Serratia marcescens	T007	C0036766
27553051	1323	1356	coagulase-negative Staphylococcus	T007	C0445625
27553051	1370	1395	Antibiotic susceptibility	T033	C0427965
27553051	1396	1411	testing results	T034	C0456984
27553051	1457	1466	organisms	T001	C0029235
27553051	1472	1483	susceptible	T169	C0231204
27553051	1491	1507	penicillin group	T109,T195	C0030842
27553051	1509	1526	No adverse events	T033	C2699517
27553051	1542	1545	use	T169	C0457083
27553051	1549	1561	intracameral	T082	C1636767
27553051	1562	1572	cefuroxime	T109,T195	C0007562
27553051	1595	1598	use	T169	C0457083
27553051	1602	1614	intracameral	T082	C1636767
27553051	1615	1625	cefuroxime	T109,T195	C0007562
27553051	1646	1652	reduce	T081	C0547047
27553051	1657	1661	rate	T081	C1521828
27553051	1665	1694	postoperative endophthalmitis	T047	C1282227
27553051	1700	1715	tertiary centre	T093	C0596660
27553051	1719	1728	Hong Kong	T083	C0019907
27553051	1734	1737	use	T169	C0457083
27553051	1741	1748	aseptic	T080	C0232920
27553051	1741	1760	aseptic compounding	T058	C0013164
27553051	1772	1782	cefuroxime	T109,T195	C0007562
27553051	1783	1791	aliquots	T081	C1510844
27553051	1795	1812	hospital pharmacy	T093	C0260123